small molecule

BRIXADI

BUPRENORPHINE

Loss of exclusivityJuly 2032latest FDA-listed patent expiry

CompanyBraeburn Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand name	BRIXADI
Active ingredient	BUPRENORPHINE
Strength	16MG/0.32ML (50MG/ML)
Dosage form	SOLUTION, EXTENDED RELEASE
Route	SUBCUTANEOUS
Modality	Small molecule
FDA approval	May 2023
Marketing status	RX

Listed patents

Patent	Expires	Type
11135215	July 2032	product
12161640	July 2032	product
11110084	July 2032	product
10912772	July 2032	use U-3617
9937164	July 2032	product
12318379	July 2032	product
8236292	January 2027	product
8236755	July 2026	product

Regulatory exclusivity

Code	Expires
NP	May 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Braeburn Pharmaceuticals